JP2020511115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511115A5 JP2020511115A5 JP2019533166A JP2019533166A JP2020511115A5 JP 2020511115 A5 JP2020511115 A5 JP 2020511115A5 JP 2019533166 A JP2019533166 A JP 2019533166A JP 2019533166 A JP2019533166 A JP 2019533166A JP 2020511115 A5 JP2020511115 A5 JP 2020511115A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- transcription factor
- acid sequence
- car
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 42
- 108091023040 Transcription factor Proteins 0.000 claims description 28
- 102000040945 Transcription factor Human genes 0.000 claims description 28
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 2
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 2
- 101000687344 Homo sapiens PR domain zinc finger protein 1 Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004186 co-expression Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022126972A JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114673A JP2024133287A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114672A JP2024133286A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1621889.3 | 2016-12-21 | ||
| GBGB1621889.3A GB201621889D0 (en) | 2016-12-21 | 2016-12-21 | Cell |
| PCT/GB2017/053834 WO2018115865A1 (en) | 2016-12-21 | 2017-12-20 | Cell expressing a car and a transcription factor and its use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126972A Division JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511115A JP2020511115A (ja) | 2020-04-16 |
| JP2020511115A5 true JP2020511115A5 (enExample) | 2020-12-03 |
| JP7149273B2 JP7149273B2 (ja) | 2022-10-06 |
Family
ID=58284380
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533166A Active JP7149273B2 (ja) | 2016-12-21 | 2017-12-20 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2022126972A Withdrawn JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114672A Pending JP2024133286A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114673A Pending JP2024133287A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022126972A Withdrawn JP2022145846A (ja) | 2016-12-21 | 2022-08-09 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114672A Pending JP2024133286A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
| JP2024114673A Pending JP2024133287A (ja) | 2016-12-21 | 2024-07-18 | Ｃａｒおよび転写因子を発現する細胞、ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200030379A1 (enExample) |
| EP (1) | EP3559213A1 (enExample) |
| JP (4) | JP7149273B2 (enExample) |
| CN (1) | CN110099997A (enExample) |
| AU (1) | AU2017380449B2 (enExample) |
| CA (1) | CA3047621C (enExample) |
| GB (1) | GB201621889D0 (enExample) |
| WO (1) | WO2018115865A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019210863A1 (zh) | 2018-05-03 | 2019-11-07 | 科济生物医药（上海）有限公司 | 免疫效应细胞及其应用 |
| US20210363217A1 (en) * | 2018-06-19 | 2021-11-25 | Autolus Limited | Cell |
| WO2020183131A1 (en) | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| WO2022103789A1 (en) * | 2020-11-10 | 2022-05-19 | Kyverna Therapeutics, Inc. | A method for treating disease using foxp3+cd4+ t cells |
| CN114805596B (zh) * | 2021-01-22 | 2023-07-14 | 华东师范大学 | 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用 |
| TW202239768A (zh) | 2021-01-27 | 2022-10-16 | 美商萊爾免疫藥物股份有限公司 | 改良之免疫細胞療法 |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| KR20230150834A (ko) | 2021-02-25 | 2023-10-31 | 라이엘 이뮤노파마, 인크. | Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열 |
| TW202246511A (zh) | 2021-02-25 | 2022-12-01 | 美商萊爾免疫藥物股份有限公司 | 靶向ny-eso-1之增強免疫細胞療法 |
| US20230052243A1 (en) | 2021-06-02 | 2023-02-16 | Lyell Immunopharma, Inc. | Nr4a-deficient cells expressing c-jun and uses thereof |
| JP2024540103A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | ｃ－Ｊｕｎを発現する細胞を培養するための方法 |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| US20250249100A1 (en) * | 2022-04-25 | 2025-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing t cell exhaustion |
| EP4525892A1 (en) | 2022-05-19 | 2025-03-26 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
| TW202413646A (zh) | 2022-07-22 | 2024-04-01 | 美商萊爾免疫藥物股份有限公司 | 免疫細胞療法 |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828982T3 (es) | 2013-05-14 | 2021-05-28 | Univ Texas | Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas |
| EP3283619B1 (en) | 2015-04-17 | 2023-04-05 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| GB201509413D0 (en) | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| WO2017035251A1 (en) * | 2015-08-25 | 2017-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells modified to overexpress c-myb |
| US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US12060394B2 (en) * | 2016-04-28 | 2024-08-13 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
-
2016
- 2016-12-21 GB GBGB1621889.3A patent/GB201621889D0/en not_active Ceased
-
2017
- 2017-12-20 CN CN201780079674.7A patent/CN110099997A/zh active Pending
- 2017-12-20 EP EP17822745.0A patent/EP3559213A1/en active Pending
- 2017-12-20 AU AU2017380449A patent/AU2017380449B2/en active Active
- 2017-12-20 CA CA3047621A patent/CA3047621C/en active Active
- 2017-12-20 US US16/470,968 patent/US20200030379A1/en not_active Abandoned
- 2017-12-20 JP JP2019533166A patent/JP7149273B2/ja active Active
- 2017-12-20 WO PCT/GB2017/053834 patent/WO2018115865A1/en not_active Ceased
-
2022
- 2022-08-09 JP JP2022126972A patent/JP2022145846A/ja not_active Withdrawn
-
2023
- 2023-11-30 US US18/525,271 patent/US20240307440A1/en active Pending
-
2024
- 2024-07-18 JP JP2024114672A patent/JP2024133286A/ja active Pending
- 2024-07-18 JP JP2024114673A patent/JP2024133287A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511115A5 (enExample) | ||
| AU2019227813B2 (en) | Neoantigen identification with pan-allele models | |
| ES3029080T3 (en) | Neoantigen identification using hotspots | |
| US11446398B2 (en) | Regulated biocircuit systems | |
| Huang et al. | Engineering genetic predisposition in human neuroepithelial stem cells recapitulates medulloblastoma tumorigenesis | |
| JP7395483B2 (ja) | ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子 | |
| US20190005191A1 (en) | Chromosome neighborhood structures and methods relating thereto | |
| CN116254231A (zh) | 等位基因编辑及其应用 | |
| JP2019525914A5 (enExample) | ||
| KR20190112271A (ko) | 난소암 및 다른 암에 대한 면역요법에 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| ITMI20071522A1 (it) | Vaccino idiotipico | |
| JPWO2019156137A5 (enExample) | ||
| JPWO2020035676A5 (enExample) | ||
| JPWO2019202322A5 (enExample) | ||
| JP2016082979A5 (enExample) | ||
| JP2017525357A5 (enExample) | ||
| JP2004290197A5 (enExample) | ||
| Choi et al. | Nuclear ribonucleoprotein condensates as platforms for gene expression regulation | |
| JP2009511036A5 (enExample) | ||
| JP2022502081A (ja) | 遺伝子操作された微生物ならびにそれを作製および使用する方法 | |
| Raghavan | Engineering minimally immunogenic cargos and delivery modalities for gene therapy | |
| Perez-Maya et al. | Complete genome sequence of Streptococcus pneumoniae serotype 19A, a blood clinical isolate from Northeast Mexico | |
| JPWO2021079122A5 (enExample) | ||
| JPWO2021247789A5 (enExample) | ||
| Esparza | IRF1 is required for chromatin remodeling in bone marrow derived macrophages upon IFN-γ activation |